ArticleDrug design, development and therapy2026
Preclinical Pharmacokinetics, ADME, and Drug-Drug Interaction Evaluation of S024, a Novel p38/MK2 Inhibitor for Rheumatoid Arthritis.
Article in Drug design, development and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Traditional Chinese Medicine Formulas in Delaying Aging: From Theoretical Foundations to Molecular Mechanisms and Translational Perspectives.Journal of cellular and molecular medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: S024 is a novel dual p38/MK2 inhibitor with therapeutic potential for rheumatoid arthritis (RA). Unlike existing RA therapies often limited by suboptimal efficacy and safety profiles, S024 selectively targets the p38/MK2 signaling complex, representing a mechanistically distinct treatment strategy. This study aimed to systematically characterize the preclinical pharmacokinetic (PK), absorption, distribution, metabolism, excretion (ADME), and drug-drug interaction (DDI) profiles of S024. Methods: Permeability was assessed using Caco-2 cell monolayers. PK and oral bioavailability were determined in Sprague-Dawley (SD) rats and beagle dogs. Plasma protein binding (PPB), tissue distribution, in vitro metabolic stability (across species), enzyme phenotyping, excretion mass balance, and DDI potential against major CYP450 enzymes and key ABC/SLC transporters were comprehensively evaluated. Results: S024 displayed low permeability in Caco-2 assays, likely attributable to P-gp-mediated efflux. Despite this, oral absorption remained efficient, with high bioavailability in rats (F%=56.3~101%) and dogs (F%=40.1~110%). S024 exhibited moderate PPB across species and minimal red blood cell distribution. Extensive tissue distribution was observed in rats, predominantly in the gastrointestinal tract and well-perfused organs. Hepatic clearance varied significantly across species, with values of 320.9, 43.8, <25.6, 25.7, and <10.3 mL/min/kg in mice, rats, dogs, monkeys, and humans, respectively. CYP2C8 and CYP3A were identified as the primary metabolic enzymes. Excretion studies confirmed that S024 was eliminated predominantly as metabolites via feces. DDI profiling revealed only modest inhibition of CYP2C8 (IC Conclusion: S024 demonstrated favorable preclinical PK/ADME properties, characterized by robust oral absorption, moderate PPB, extensive distribution, and a low predicted clinical DDI risk. These findings strongly support its further development as a promising clinical candidate for RA therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.